[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 6 sources · 5 days · First seen · Last updated

Iovance Biotherapeutics market performance

Overview

Iovance Biotherapeutics experienced significant stock growth driven by positive analyst sentiment and improved financial outlooks. Initially, shares reached a 52-week high following a Goldman Sachs upgrade to a ‘buy’ rating, with analysts citing the performance of the melanoma drug Amtagvi as a key driver.

This momentum continued as the company sharply increased its 2026 revenue forecast, raising guidance to between $410 million and $420 million from a previous range of $350 million to $370 million. This upward revision, representing nearly 60% annual growth, is attributed to accelerating demand for Amtagvi and Proleukin, alongside the expansion of authorized treatment centers, with a goal of reaching at least 110 centers by the end of the year.

Following the revenue guidance update, H.C. Wainwright maintained a ‘Buy’ rating and significantly raised its price target for the stock from $9 to $20.

Entities

Iovance Biotherapeutics · Goldman Sachs · Barclays · BlackRock Inc. · Amtagvi

Timeline

  1. [BUSINESS] 4 sources
    Iovance Biotherapeutics shares surge on raised 2026 revenue forecast

    Iovance Biotherapeutics shares hit a two-year high after the company raised its 2026 revenue forecast to $410 million-$420 million, driven by high demand for its melanoma treatment, Amtagvi.

  2. [BUSINESS] 2 sources
    Iovance Biotherapeutics shares hit new high following analyst upgrade

    Iovance Biotherapeutics shares hit a 52-week high after Goldman Sachs upgraded the stock to a buy, citing strong sales of its melanoma treatment, Amtagvi.

Sources

cfodive.com · greenmountain.no · ibtimes.com.au · newsable.asianetnews.com · stocknews.com · theascent.com

This summary has been updated 1 time: see revision history